Autolus Therapeutics plc (FRA:6A3A)

Market Cap	323.63M
Revenue (ttm)	43.58M
Net Income (ttm)	-191.60M
Shares Out	n/a
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155
Average Volume	307
Open	1.170
Previous Close	1.250
Day's Range	1.170 - 1.200
52-Week Range	1.000 - 3.220
Beta	n/a
RSI	49.63
Earnings Date	Mar 12, 2026

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 650
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6A3A

Financial Performance

In 2024, Autolus Therapeutics's revenue was $10.12 million, an increase of 496.00% compared to the previous year's $1.70 million. Losses were -$220.66 million, 5.89% more than in 2023.

Financial numbers in USD